Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19103054 | 1.00 | DNM1 (0.57) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3626123 | 1.00 | DNM1 (0.57) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3624962 | 1.00 | DNM1 (0.57) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL11028322 | 0.97 | DNM1 (0.52) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24107253 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1164952 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL1688008 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20017999 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3620472 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL3617767 | 0.95 | DNM1 (0.65) | DNM1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002730-A1 | OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-06 | — | — | US | disclosed |
| US-11028078-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002730-A1 | OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF | NFKBIA, IKBKB, NFRKB | DNM1 3013/4885ALDH1A1 4651/4885MEN1 4750/4885 |
| US-20190040046-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | DNM1 1910/4885ALDH1A1 1448/4885MEN1 3871/4885 |
| US-11028078-B2 | Itraconazole analogs and use thereof | SHH, GLI1, KDR | DNM1 1910/4885ALDH1A1 1448/4885MEN1 3871/4885 |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | DNM1 1277/4885ALDH1A1 255/4885MEN1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.